Quest Diagnostics Inc. stock outperforms competitors despite losses on the day
Quest Diagnostics Inc. (DGX) shares fell by 1.05% to $213.45 on Monday, marking a second consecutive day of losses for the company. Despite this, the stock underperformed the broader market, which saw the S&P 500 Index (SPX) rise by 0.72% and the Dow Jones Industrial Average (DJIA) increase by 0.29%.
Labcorp Holdings (LH) Expands Cancer And Liver Testing, Is It Fully Priced?
Labcorp Holdings (LH) is gaining attention due to recent advancements in cancer and liver testing, including the nationwide Medicare-covered launch of its ColoSense colorectal screening kit. Despite strong share price performance, the company is considered approximately 7.5% undervalued with a fair value estimate of $310, driven by anticipated revenue growth from strategic collaborations and innovative test introductions. However, potential risks from tariffs and regulatory shifts could impact this positive outlook.
Quest Diagnostics stock steady as investors await the next catalyst
Quest Diagnostics stock remains stable as investors anticipate future company-specific updates, with its business centered on diagnostic and lab services. The company's performance is closely tied to U.S. healthcare demand, testing volumes, and reimbursement trends, which are key watchpoints for investors on quiet catalyst days. The core business involves laboratory testing, supporting clinicians and health systems, and its shares trade on the NYSE.
NEO - Neogenomics Inc Latest SEC Filings
This article provides the latest SEC filings information for Neogenomics Inc (NEO), along with a detailed overview of its financial data, stock performance metrics, and key ratios. It includes market capitalization, income, sales, EPS, insider ownership, institutional ownership, and various performance indicators.
Quest Diagnostics (DGX) Could Be 4% Undervalued On Haystack MRD Approval
Quest Diagnostics (DGX) recently received New York State approval for its Haystack MRD liquid biopsy test, allowing clinical use across all 50 states and expanding its cancer diagnostics reach. The company's stock has seen a 24.13% year-to-date return, suggesting strong momentum. Despite trading near its analyst target, the article explores whether the Haystack MRD approval and new partnerships indicate further upside, valuing the stock as modestly undervalued at $223.44 against a current price of $215.72.
Quest Diagnostics Quantiferon-TB Gold Plus - lab test quietly underpins US tuberculosis screening
Quest Diagnostics' (NYSE: DGX) Quantiferon-TB Gold Plus is a blood-based test critical for US tuberculosis screening, especially for work visas, healthcare jobs, and in settings like hospitals and shelters. This interferon gamma release assay offers an alternative to traditional skin tests, particularly beneficial for BCG-vaccinated individuals by avoiding false positives and streamlining compliance workflows. The test integrates into Quest Diagnostics' national lab network, contributing to its recurring revenue from advanced diagnostics.
GRAL - GRAIL Inc Volatility & Greeks
This article provides a detailed financial overview of GRAIL Inc. (GRAL), including key metrics such as market capitalization, income, sales, various performance ratios, and stock performance indicators. It also lists insider and institutional ownership, analyst recommendations, and volatility measures. The data reflects the company's financial health, operational efficiency, and market sentiment, with the last close at $68.95.
Quest Diagnostics highlights long-term testing role in U.S. healthcare
Quest Diagnostics continues its central role in U.S. diagnostic testing, with investors focusing on its long-term positioning in laboratory services and routine screening demand. The company is a major provider of diagnostic information services, offering a broad range of tests that are crucial for medical checkups, chronic disease management, and preventive screenings. Its extensive network and focus on digital integration and operational efficiency support its sustained relevance in the competitive healthcare market.
DGX - Quest Diagnostics Inc Volatility & Greeks
This article provides a detailed financial snapshot of Quest Diagnostics Inc. (DGX), including key metrics such as market capitalization, earnings per share, sales performance, and various financial ratios. It also presents volatility figures, dividend information, analyst recommendations, and recent price performance, offering a comprehensive overview for potential investors.
How Investors Are Reacting To Quest Diagnostics (DGX) New MRD Test Milestone And Attunio Partnership
Quest Diagnostics recently achieved a significant milestone with its Haystack MRD liquid biopsy test gaining New York State approval, making it available nationwide. This, combined with a new partnership with Attunio Health, reinforces Quest's position in advanced oncology diagnostics and its role as a national "lab backbone." Investors are weighing these positive developments against ongoing industry pressures like reimbursement cuts and rising costs, with fair value estimates for DGX varying among analysts.
MEDP - Medpace Holdings Inc Latest SEC Filings
This article provides the latest SEC filings information for Medpace Holdings Inc (MEDP), along with comprehensive financial data, key performance indicators, and company statistics. It details various financial ratios, insider and institutional ownership, profitability margins, and stock performance metrics for the company.
If You Invested $1,000 in Quest Diagnostics Inc (DGX)
This article analyzes the historical performance of investing $1,000 in Quest Diagnostics Inc (DGX) over varying periods, showing significant returns over 1, 5, and 10 years, though underperforming the S&P 500 in the long term. It also provides a detailed overview of Quest Diagnostics' business model, its role in the healthcare ecosystem, its leadership in diagnostic testing, and its innovations in specialized diagnostics like oncology and neurology. The company's financial overview and market presence are also highlighted.
Quest Diagnostics outlines its role in medical testing as investors weigh long-term demand
Quest Diagnostics, a leading US provider of diagnostic information services, plays a crucial role in healthcare testing, digital lab reporting, and chronic disease management. The company operates an extensive network of laboratories and patient service centers, processing millions of tests annually. Its stock is seen as a long-term investment in the resilient healthcare services sector, driven by an aging population and increasing demand for routine and specialized testing.
OPK - Opko Health Inc Options
This article provides a comprehensive overview of Opko Health Inc. (OPK) stock, including its latest closing price, key financial metrics, performance indicators, and ownership details. It details statistics such as market capitalization, income, sales, P/E ratio, EPS, insider and institutional ownership, and various performance percentages over different periods.
Quest Diagnostics highlights its role in US healthcare. The stock reflects a stable diagnostics busi
The article highlights Quest Diagnostics' significant role in the US healthcare system as a leading provider of diagnostic information services. It details the company's business model, which relies on high-volume clinical laboratory testing, strong payer relationships, and advanced digital infrastructure. The company's stability is attributed to its operational scale, continuous innovation, and adaptation to structural growth drivers in diagnostics, positioning it as a key player in supporting clinical decisions and public health.
FLGT - Fulgent Genetics Inc Forecast, Target Price
This article provides a detailed financial overview and forecast for Fulgent Genetics Inc (FLGT). It includes key metrics such as market capitalization, income, sales, earnings per share, and stock performance indicators. The report also highlights analyst recommendations and a target price for the company's stock.
Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics
Labcorp (LH) saw its stock rise by 7.7% after announcing new peer-reviewed evidence for its MVX and NIS2+ blood tests for metabolic liver disease and the nationwide U.S. launch of ColoSense, an FDA-approved, RNA-based at-home colorectal cancer screening test now covered by Medicare. These developments underscore Labcorp's focus on less invasive and accessible diagnostics for early detection of liver and colorectal diseases. The company's strategy involves expanding its test breadth to capture more volume and offset reimbursement pressures, though investors are advised to also consider potential impacts from changing reimbursement policies.
Director Timothy Wentworth receives 144 DGX phantom units as deferred pay
Quest Diagnostics director Timothy C. Wentworth received 144 Phantom Stock Units as deferred cash compensation, increasing his total holdings to 342 units. These units are tied to Quest Diagnostics common stock value but are payable in cash upon his termination of service, not representing an open-market stock transaction. This is a routine compensation-related grant under the company's Deferred Compensation Plan for Directors.
Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?
NeoGenomics (NEO) has appointed Carolyn Starrett, a former Flatiron Health CEO known for her expertise in AI and healthcare data, to its Board of Directors. This move, combined with its Epic Aura integration, suggests NeoGenomics is enhancing its oncology data strategy to differentiate its services and improve long-term growth. While this could lead to more predictable growth and narrower losses by leveraging AI and real-world data, investors should be aware of the inherent risks, including ongoing losses and revenue volatility from pharma and biotech demand.
Quest Diagnostics steadies after recent volatility as investors focus on core testing business
Quest Diagnostics is navigating recent market volatility by focusing on its core diagnostic services and extensive laboratory network. The company's large scale, diversified revenue base from institutional and individual demand, and ongoing investments in automation and data analytics contribute to its long-term appeal for investors. Strategic partnerships with healthcare providers and the resilient demand for laboratory testing driven by demographic trends and chronic diseases underpin its growth prospects.
UnitedHealth Group Covers Shield Blood Test for Colorectal Cancer Screening
UnitedHealth Group has expanded coverage for Guardant Health's Shield blood test, making it available for colorectal cancer screening to eligible members aged 45 and older. This move significantly increases access to the FDA-approved blood test for approximately 40 million people across various UnitedHealth Group plans. The expansion is crucial as colorectal cancer rates are rising in younger populations, offering a more accessible screening alternative to traditional methods.
Waters to hold Q2 2026 results call Aug. 4, webcast set
Waters Corporation (NYSE: WAT) has scheduled its second-quarter 2026 financial results conference call for Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay of the presentation will be available on the company's Investor Relations website until at least September 1, 2026. This announcement provides key financial reporting dates for investors and signals a period of updates following recent corporate activities.
DGX - Quest Diagnostics Inc Options
This article provides a comprehensive financial overview of Quest Diagnostics Inc. (DGX), including its market performance, valuation metrics, dividend information, and growth rates. Key financial data points such as P/E ratio, market capitalization, sales, and various performance indicators are detailed.
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market
20/20 Biolabs (AIDX) outlined its OneTest multi-cancer early detection strategy, which includes a focus on future Medicare reimbursement and a protein biomarker-based test. The company is aligning its strategy with the new Multi-Cancer Early Detection Screening Coverage Act, aiming for Medicare coverage of MCED tests starting in 2028, contingent on FDA authorization and CMS clinical appropriateness. The presentation also detailed an M&A strategy targeting health-and-wellness businesses and included hypothetical revenue projections and a royalty pool for "data investors."
Quest Diagnostics's Q2 2026 Earnings: What to Expect
Quest Diagnostics (DGX) is set to release its Q2 2026 earnings on July 23, with analysts projecting an adjusted EPS of $2.81, a 7.3% increase year-over-year. The company has a history of exceeding Wall Street's earnings estimates and recently reported strong Q1 2026 results which led to a raised full-year outlook. Analysts currently have a "Moderate Buy" rating for DGX, with an average price target that suggests a modest upside.
Baird initiates Abbott stock coverage with Outperform rating
Baird has initiated coverage on Abbott Laboratories (NYSE:ABT) with an Outperform rating and a price target of $121, indicating a 33% upside. The firm anticipates steady 6-8% top-line and earnings growth for Abbott, driven by its strong medical devices business and strategic integrations. Abbott is considered undervalued, a prominent player in its industry, and has consistently raised its dividend for 12 years.
MYGN - Myriad Genetics Inc Latest SEC Filings
This article provides the latest SEC filings and detailed financial data for Myriad Genetics Inc. (MYGN), including key metrics like market capitalization, income, sales, P/E ratios, and stock performance data. It also lists insider and institutional ownership, profitability margins, and various technical indicators, offering a comprehensive snapshot of the company's financial health and stock activity.
Labcorp consensus stays steady, S&P 500 peer group frames the stock
Labcorp (US50540R4092) maintains a stable analyst consensus as it begins the week, positioning itself within the S&P 500 healthcare sector. The company's performance is driven by its diagnostic and central lab services, with investors keenly observing upcoming earnings and broader sector trends. Analysts' price targets are typically based on mid-to-high single-digit revenue growth and mid-teen operating margins for its core laboratory business.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Quest Diagnostics Inc. (DGX) shares rose 1.32% to $212.64 on Monday, marking its fifth consecutive day of gains. The stock's performance outpaced the broader market, with the S&P 500 Index and Dow Jones Industrial Average also seeing increases. This positive movement occurred during a strong trading session for the overall stock market.
Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE
Quest Diagnostics' upcoming quarterly earnings are drawing investor attention as the healthcare diagnostics group prepares for its next update on the NYSE. Analysts largely view the shares as fairly valued, anticipating stable revenue growth and consistent margin profiles, reflecting steady demand for diagnostic testing services. The company's performance, which reports on routine and advanced diagnostics, is a key indicator for broader healthcare spending and trends in the US.
Guardant Health (GH) Stock After 193% One-Year Gain Is The Rally Running Out Of Room
Guardant Health (GH) has seen a 193% one-year gain, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is currently trading at a small 6.2% discount to its intrinsic value, indicating it is "about right" for its current price of $149. However, its Price/Sales (P/S) ratio of 18.32x is significantly higher than the industry average and Simply Wall St's Fair Ratio of 7.86x, suggesting the stock might be overvalued based on this metric.
Price to earnings forward of Quest Diagnostics Incorporated – NYSE:DGX
The article provides financial information for Quest Diagnostics Incorporated (NYSE: DGX), specifically focusing on its "Price to earnings forward" metric. It details the company's market information, including its stock exchange listing and the current market status. The content appears to be a financial data snippet from a platform like TradingView, stating "No trades" as the market is closed.
Labcorp focuses on long-term strategy, shares supported by healthcare demand
Labcorp is undergoing a multi-year transformation of its diagnostics and drug-development businesses, supported by steady healthcare demand and insurance spending. The company reported first-quarter 2026 revenue of approximately $3.2 billion, driven by strong testing volumes and central laboratory services for pharmaceutical trials, with a focus on high-growth areas like specialty diagnostics. Labcorp (LH) shares recently traded around $271 on the NYSE, with a market capitalization near $22 billion.
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains
Quest Diagnostics Inc. (DGX) shares rose 1.76% to $209.88 on Friday, marking its fourth consecutive day of gains. Despite this increase, the stock underperformed compared to the broader market, as the S&P 500 Index fell 0.05% and the Dow Jones Industrial Average dropped 0.09% on the same day.
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
This article reviews the Q1 earnings of several testing and diagnostics services stocks, highlighting NeoGenomics (NEO), Guardant Health (GH), RadNet (RDNT), Labcorp (LH), and Quest Diagnostics (DGX). It notes that the industry as a whole reported strong Q1 results, with revenues beating estimates and share prices performing well. Guardant Health was identified as the top performer, while Labcorp had the weakest performance against analyst estimates.
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Quest Diagnostics has received approval from the New York State Department of Health for its Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy for detecting residual or recurring disease in solid tumor cancer patients. This approval, following a rigorous review, broadens access to the test across all 50 U.S. states. The test's clinical utility has been demonstrated in studies, including a landmark investigation at Memorial Sloan Kettering Cancer Center, which highlighted its reliability in identifying clinical complete response earlier than traditional imaging methods.
Quest Diagnostics Incorporated Actuals & Estimates (NYSE:DGX)
This article provides an overview of Quest Diagnostics Incorporated (NYSE: DGX), including its current stock price, historical performance, analyst forecasts, and financial data. It covers key metrics like market capitalization, earnings per share, revenue, net income, dividends, and volatility, offering a comprehensive financial snapshot for potential investors.
Q1 Earnings Highlights: Labcorp (NYSE:LH) Vs The Rest Of The Testing & Diagnostics Services Stocks
This article analyzes the Q1 2026 earnings for Labcorp (NYSE:LH) and other companies in the testing & diagnostics services industry. While Labcorp reported satisfactory results, Guardant Health (NASDAQ:GH) emerged as the best performer with significant revenue growth and a positive market reaction. The article also discusses the broader industry trends and challenges, including the impact of AI and geopolitical risks on market psychology.
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of Quest Diagnostics Inc. (DGX) rose 1.54% on Thursday, marking its third consecutive day of gains. However, the stock underperformed compared to its competitors, despite the overall mixed trading session where the Dow Jones Industrial Average saw a slight increase and the S&P 500 Index experienced a minor decline.
Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs
Attunio Health has announced a significant expansion of its AI-powered precision psychiatry platform by partnering with Quest Diagnostics and integrating Getlabs for at-home blood collection. This move strengthens Attunio's infrastructure for continuous, objective, data-driven mental healthcare, moving beyond traditional subjective symptom reporting. The platform combines AI insights, physiological data, biomarker and genetic testing, and behavioral observation to provide a "Closed-Loop Precision Psychiatry" model, aiming to make advanced diagnostic testing more accessible nationwide.
DGX Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast for Quest Diagnostics Incorporated (DGX) stock, including analyst price targets, current stock performance, and historical data. It also covers financial metrics like EPS, revenue, market capitalization, and dividend information, addressing frequently asked questions about investing in DGX.
Quest Diagnostics stock rises after New York approves cancer test
Quest Diagnostics (NYSE:DGX) shares rose after New York State approved its Haystack MRD test for identifying residual or recurring solid tumor cancers. This approval makes the test available nationwide, as New York was the final state needed for full U.S. availability. The Haystack MRD test, which identifies cancer recurrence earlier than traditional imaging, was developed under CLIA regulations and demonstrated clinical utility in a study published in The New England Journal of Medicine.
Quest Diagnostics Receives New York Clearance for Haystack MRD Test
Quest Diagnostics has received clearance from New York State for its Haystack MRD Test, a significant step for the company's diagnostics services. The Haystack MRD Test specializes in minimal residual disease detection, which is crucial for monitoring cancer recurrence. This clearance expands the availability of advanced diagnostic testing in a key market.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Quest Diagnostics Inc. (DGX) shares rose 3.01% to $203.11 on Wednesday, outperforming the mixed stock market where the Dow Jones Industrial Average gained and the S&P 500 Index declined. This marks the second consecutive day of gains for the stock.
Quest Diagnostics stock rises after New York approves cancer test
Quest Diagnostics (NYSE:DGX) shares rose 2.2% after the New York State Department of Health approved its Haystack MRD test. This approval makes the circulating tumor DNA liquid biopsy test available in all 50 U.S. states for identifying residual or recurring disease in solid tumor cancer patients. The test, developed under CLIA regulations, aims to detect residual disease earlier and identify recurrence before it becomes clinically apparent, with a study demonstrating its effectiveness in detecting clinical complete response significantly faster than imaging methods.
Quest Diagnostics stock rises after New York approves cancer test By Investing.com
Quest Diagnostics (NYSE:DGX) shares rose 2.2% after the New York State Department of Health approved its Haystack MRD test. This approval allows the circulating tumor DNA liquid biopsy test to be offered in New York, making it available nationwide across all 50 U.S. states. The test is designed to detect residual or recurring disease in solid tumor cancer patients earlier and has shown clinical utility in studies.
Quest Diagnostics stock rises after New York approves cancer test By Investing.com
Quest Diagnostics (NYSE:DGX) shares rose 2.2% after its Haystack MRD test received approval from the New York State Department of Health. This approval makes the circulating tumor DNA liquid biopsy test available nationwide, allowing it to identify residual or recurring disease in solid tumor cancer patients. The test's clinical utility was demonstrated in a study showing earlier detection of clinical complete response compared to imaging methods.
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing – Company Announcement - FT.com
Quest Diagnostics has received approval from the New York State Department of Health for its Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test. This approval allows for its use in identifying residual or recurring disease in patients with solid tumor cancers across all 50 U.S. states. The test, developed under CLIA regulations, has demonstrated clinical utility in rigorous investigational settings, including a landmark study for non-operative management of dMMR solid tumors.
New York clears Quest Diagnostics' cancer recurrence test statewide
Quest Diagnostics (NYSE: DGX) has received New York State Department of Health CLEP approval for its Haystack MRD® ctDNA liquid biopsy test, which identifies residual or recurring disease in solid tumor cancers. This approval expands the test's availability to all 50 U.S. states. Clinical data supports the test's utility, showing it can detect complete clinical response at a median of 1.4 months, significantly faster than traditional imaging methods.
Does Labcorp’s New RNA At‑Home ColoSense Screening Win Shift The Bull Case For LH?
Labcorp has launched ColoSense, an FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare, expanding its at-home screening portfolio. This launch aligns with Labcorp's strategy for diagnostic innovation and growth, aiming to integrate with tools like the MyLabcorp AI app to enhance patient connection and test adoption. While it strengthens Labcorp's oncology focus, investors should still consider broader challenges like reimbursement changes and competition.
